Clinical Trial Update: Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and immunogenicity of a single dose of the NDV 3A vaccine in individuals with STAT3-mutated Hyper-IgE syndrome (Au…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Hyper-ige Syndrome
• Hyper-ige Syndrome

Drugs mentioned

• NDV-3A vaccine (NDV-3A)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Autosomal-dominant Hyper-IgE Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2020-06-30